Jeff Allen: How Can Real-World Data Be Used To Measure Treatment Response Rates?
Jeff Allen, President and CEO of Friends of Cancer Research, shared a post on LinkedIn:
“NEW PUBLICATION – Results from our latest Real-World Evidence Pilot demonstrate how treatment response rate can be measured using real-world data.
Data obtained from clinical practice, or real-world data (RWD), can provide valuable insights about treatment outcomes – particularly for patient populations not fully represented in prior clinical studies or for exploring potential other uses for new medicines. However, use of RWD as a research tool can require different methods and study considerations.
In our new study published in JCO CCI, we show that different sources of data can be used to implement a common approach and consistently evaluate response rates. This aligned method and reproducibility in results show that rwResponse can be a valuable metric to assess treatment effectiveness outside of traditional clinical trials.
Authors: Brittany A. McKelvey , Elizabeth Garrett-Mayer, Donna R. Rivera , Amy Alabaster, Hillary S. Andrews, Elizabeth G. Bond, Thomas D. Brown, Amanda Bruno, Lauren Damato, , Janet L. Espirito, Laura L. Fernandes, Eric Hansen, Paul Kluetz, Xinran Ma, Andrea McCracken, Pallavi S. Mishra-Kalyani, Yanina Natanzon, Danielle Potter, Nicholas J. Robert, Lawrence Schwartz, Regina Schwind, Connor Sweetnam, Joseph Wagner, Mark D. Stewart and Jeff D. Allen.”
RWE project page.
Receive regular updates.
Many thanks to our collaborators: American Society of Clinical Oncology (ASCO), ConcertAI, COTA, FDA, Flatiron Health, Friends of Cancer Research, Guardian Research Network, IQVIA, Memorial Sloan Kettering Cancer Center, Ontada, Syapse, Syneos Health, and Tempus AI.
Authors: Brittany A. McKelvey, Elizabeth Garrett-Mayer, Donna R. Rivera, Amy Alabaster, Hillary S. Andrews, Elizabeth G. Bond, Thomas D. Brown and Jeff D. Allen.”
